Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Diamond Equity Research Update Sep 2023 Valuation at 70 cents per share

Friday, October 20, 2023 1 min read
Key Takeaway: Diamond Equity Research has updated its valuation for Radiopharm Theranostics (RADX) to 70 cents per share. This update comes amidst positive clinical developments, including the dosing of the first patient in a Phase 1/2a clinical study of BetaBart (RV-01) and recent FDA IND approval for a new therapeutic study targeting B7H3. The outlook appears optimistic based on these advancements.

Market Sentiment Analysis

POSITIVE FACTORS

  • Valuation update indicates potential growth for RADX.
  • Positive clinical updates across multiple programs.
  • Recent IND approval from the FDA for a new therapeutic study.

Full Press Release Details

• Updates
• PDF
• October 20, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• July 20, 2023
• Announcements
• December 17, 2021
• Announcements
• December 9, 2022
• Announcements
• November 8, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the new valuation for RADX?

The new valuation for Radiopharm Theranostics (RADX) is set at 70 cents per share.

What recent clinical study has RADX initiated?

RADX has initiated a Phase 1/2a clinical study of BetaBart (RV-01).

What approval did RADX recently receive from the FDA?

RADX received IND approval from the FDA to initiate a therapeutic clinical study targeting B7H3.

What are the positive updates for RADX?

RADX has provided positive clinical updates across multiple programs, enhancing its outlook.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval clinical updates
Last updated: Oct 20, 2023